Pills masthead

News Releases

Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015

2014201320122011201020092008200720062004

2013 Archives

Dec 19, 2013

Philadelphia, PA – December 19, 2013 – Lannett Company, Inc. (NYSE: LCI) today announced that it has established a new, five-year $50 million revolving credit facility with a syndicate...

More
Dec 3, 2013

Philadelphia, PA – December 3, 2013 – Lannett Company, Inc. (NYSE MKT: LCI) today announced that the company will present at the Oppenheimer 24th Annual Healthcare Conference on...

More
Dec 2, 2013

Philadelphia, PA – December 2, 2013 – Lannett Company, Inc. (NYSE MKT: LCI) today announced that it will transfer the listing of its common stock to the New York Stock Exchange (NYSE)...

More
Nov 7, 2013
Adjusted EPS of $0.22 Exceeds Expectations; Company Revises Fiscal 2014 Guidance Upward
Oct 31, 2013
Company to Report Full Financial Results, Host Conference Call on Thursday, November 7th

Philadelphia, PA – October 31, 2013 – Lannett Company, Inc. (NYSE MKT: LCI) today announced that it expects to report fiscal 2014 first quarter net sales of approximately $45 million...

More
Oct 9, 2013

Philadelphia, PA – October 9, 2013 – Lannett Company, Inc. (NYSE MKT: LCI) has closed its previously announced underwritten public offering of 5,869,566 shares of the Company’s...

More
Oct 8, 2013
Company Completes Key Step in Process to Submit Product Application

Philadelphia, PA – October 8, 2013 – Lannett Company, Inc. (NYSE MKT: LCI) today announced that it has successfully completed a key step in its effort to submit to the U.S. Food and...

More
Oct 4, 2013

Philadelphia, PA – October 4, 2013 – Lannett Company, Inc. (NYSE MKT: LCI) today announced the pricing of an underwritten public offering of 5,869,566 shares of the Company’s common...

More
Oct 3, 2013

Philadelphia, PA – October 3, 2013 – Lannett Company, Inc. (NYSE MKT: LCI) today announced that it and certain selling stockholders intend to offer shares of the Company’s common...

More
Sep 10, 2013

Philadelphia, PA – September 10, 2013 – Lannett Company, Inc. (NYSE MKT: LCI) today reported financial results for its fiscal 2013 fourth quarter and full year ended June 30, 2013. For...

More
Aug 29, 2013

Philadelphia, PA – August 29, 2013 – Lannett Company, Inc. (NYSE MKT: LCI) today announced that it will report financial results for its fiscal 2013 fourth quarter and full year on...

More
Aug 13, 2013

Philadelphia, PA – August 19, 2013 – Lannett Company, Inc. (NYSE MKT: LCI), a manufacturer of generic pharmaceuticals, today announced that it has extended its contract with Jerome...

More
Aug 9, 2013

Philadelphia, PA – August 9, 2013 – Lannett Company, Inc. (NYSE MKT: LCI) today announced that the company will present at the Canaccord Genuity 33rd Annual Growth Conference on...

More
Jun 30, 2013

Philadelphia, PA – June 3, 2013 – Lannett Company, Inc. (NYSE MKT: LCI), a manufacturer of generic pharmaceuticals, today announced the appointment of James M. Maher to its Board of...

More
May 8, 2013
Net Sales Increase 27%; Net Income More than Doubles; Company Increases Guidance for Full Year
Apr 23, 2013

Philadelphia, PA – April 23, 2013 – Lannett Company, Inc. (NYSE MKT: LCI) today announced that the company will present at the Needham’s 12th Annual Healthcare Conference on...

More
Mar 12, 2013

Philadelphia, PA – March 12, 2013 – Lannett Company, Inc. (NYSE MKT: LCI) today announced that the company will present at the 25th Annual Roth Conference on Monday, March 18, 2013, at...

More
Feb 7, 2013
Growth Momentum Continues with 32% Sales Increase; Company Increases Guidance for Full Year

Philadelphia, PA – February 7, 2013 – Lannett Company, Inc. (NYSE MKT: LCI) today reported continued strong momentum, with sharply improved financial results for its fiscal 2013 second...

More
Jan 31, 2013
Net sales and eps up sharply from prior year period

Philadelphia, PA – January 31, 2013 – Lannett Company, Inc. (NYSE MKT: LCI) today announced that it expects to report net sales of approximately $36 million and diluted earnings per...

More
 
Price Data
NYSELCI